Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen

Human Vaccines

Volumn 6, Issue 6, 2010, Pages 462-466

  Gao, Yan Li ^a   Gao, Shan ^a   Kang, Lin ^a   Nie, Cong ^a   Wang, Jing Lin ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Botulinum neurotoxin; Clostridium botulinum; Hc fragment; Immunogen; Vaccine candidate

Indexed keywords

BOTULINUM TOXIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BOTULISM; CONTROLLED STUDY; DRUG PURIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; LD 50; MOLECULAR CLONING; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROPHYLAXIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

EID: 77956658135     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.6.11709     Document Type: Article

References (22)

1. Krysinski EP, Sugiyama H. Purification and some properties of H chain subunit of type A botulinum neurotoxin. Toxicon 1980; 18:705-10. (Pubitemid 11186221)
2. Sakaguchi G. Clostridium botulinum toxins. Pharmacol Ther 1982; 19:165-94.
3. Swaminathan S, Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol 2000; 7:693-9.
4. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: medical and public health management. Jama 2001; 285:1059-70.
5. Holley JL, Elmore M, Mauchline M, Minton N, Titball RW. Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin. Vaccine 2000; 19:288-97.
6. Woodward LA, Arimitsu H, Hirst R, Oguma K. Expression of HC subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice. Infect Immun 2003; 71:2941-4.
7. Smith LA. Development of recombinant vaccines for botulinum neurotoxin. Toxicon 1998; 36:1539-48.
8. Smith LA, Jensen MJ, Montgomery VA, Brown DR, Ahmed SA, Smith TJ. Roads from vaccines to therapies. Mov Disord 2004; 19:48-52.
9. Yu YZ, Sun ZW, Li N, Wang S, Wang RL, Yu WY. Protection with a recombinant Hc of Clostridium botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine. Immunopharmacol Immunotoxicol 2008; 1-11.
10. Yu YZ, Li N, Wang RL, Zhu HQ, Wang S, Yu WY, et al. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Clin Vaccine Immunol 2008; 15:1819-23.
11. Yang LM, Wang JL, Hu MT. Immunogenicity and overexpression of PCR-synthesizing gene of heavy chain C-terminal binding domain from botulinum neurotoxin type A. Chin J Microbiol Immunol 2006; 26:37-41.
12. Wang LM, Kang L, Jia HL. Generation and characterization of monoclonal antibodies against botulinum neurotoxin type A (BoNT/A). Chin J Cell Mol Immunol 2004; 20:83-5.
13. Smith LA, Rusnak JM. Botulinum neurotoxin vaccines: past, present and future. Crit Rev Immunol 2007; 27:303-18.
14. Byrne MP, Smith LA. Development of vaccines for prevention of botulism. Biochimie 2000; 82:955-66.
15. Clayton MA, Clayton JM, Brown DR, Middlebrook JL. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun 1995; 63:2738-42.
16. Swietnicki W. Folding aggregated proteins into functionally active forms. Curr Opin Biotechnol 2006; 17:367-72. (Pubitemid 44163450)
17. Cleland J. Impact of protein folding on biotechnology. In: Cleland JL, ed. Protein Folding: In Vivo and In Vitro. New York: American Chemical Society 1993; 1-22.
18. Takeda M, Kasai H, Torii Y, Mukamoto M, Kohda T, Tsukamoto K, et al. Protective effect of botulinum C/D mosaic toxoid against avian botulism. J Vet Med Sci 2006; 68:325-30.
19. Steinman A, Chaffer M, Elad D, Shpigel NY. Quantitative analysis of levels of serum immunoglobulin G against botulinum neurotoxin type D and association with protection in natural outbreaks of cattle botulism. Clin Vaccine Immunol 2006; 13:862-8. (Pubitemid 44409624)
20. Lee JS, Pushko P, Parker MD, Dertzbaugh MT, Smith LA, Smith JF. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect Immun 2001; 69:5709-15. (Pubitemid 32786509)
21. Byrne MP, Smith TJ, Montgomery VA, Smith LA. Purification, potency and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 1998; 66:4817-22.
22. Prabakaran S, Tepp W, DasGupta BR. Botulinum neurotoxin types B and E: purification, limited proteolysis by endoproteinase Glu-C and pepsin, and comparison of their identified cleaved sites relative to the three-dimensional structure of type A neurotoxin. Toxicon 2001; 39:1515-31. (Pubitemid 32722038)